ALAN BASH

CIK 1908421 · Interim CEO · last filed 2026-08-18

ALAN BASH is an Interim CEO who has filed 3 SEC Form 4 insider transactions across 2 companies since 2022. The most recent filing, for LEGN, was dated Aug 18, 2026. Current disclosed insider exposure totals $756.3K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$756.3K

Companies

2

Total Filings

3

Lifetime Open-Market Net

$0

Filer Profile

Reported Address

C/O CHECKMATE PAHRMACEUTICALS, INC.
245 MAIN STREET 2ND FLOOR
CAMBRIDGE, MA 02142

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
LEGN	Interim CEO	35,142	$21.52	$756.3K	$0	1	2026-08-18
Checkmate Pharmaceuticals, Inc. (CMPI) Delisted	Chief Executive Officer	—	$10.50	—	$0	2	2022-05-31

Recent Filings

3 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-08-18	LEGN	Grant (A)	+4,908	$0	EDGAR
2022-05-31	Checkmate Pharmaceuticals, Inc. (CMPI) Delisted	Disp (D)	—	$0	EDGAR
2022-03-02	Checkmate Pharmaceuticals, Inc. (CMPI) Delisted	Grant (A)	—	$0	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.